Scholar Rock skyrockets following SAPPHIRE trial achieving primary endpoint Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Scholar Rock (SRRK) up 216% after reporting its SAPPHIRE clinical trial, evaluating the efficacy and safety of apitegromab, achieved its primary endpoint
- Duckhorn Portfolio (NAPA) up 101% after announcing it will be acquired by private equity funds managed by Butterfly in an all-cash transaction that values the company at approximately $1.95B
- Arcadium Lithium (ALTM) up 33% after confirming that it has been approached by Rio Tinto (RIO) regarding a potential acquisition of the company
- Barnes Group (B) up 2% after announcing that it has entered into a definitive agreement to be acquired by funds managed by affiliates of Apollo Global Management (APO) in an all-cash transaction that values Barnes at an enterprise value of approximately $3.6B, or $47.50 per share in cash
- Pfizer (PFE) up 2% after The Wall Street Journal reported Starboard Value has taken a $1B stake in Pfizer and wants the company to make changes
LOWER -
- Trevena (TRVN) down 49% after receiving notice that Nasdaq had determined to delist the company's common stock
- Mullen Automotive (MULN) down 5% after forecasting $75M in estimated GAAP revenue over the next six months
- Amazon (AMZN) down 1% after Wells Fargo downgraded the stock to Equal Weight from Overweight with a price target of $183, down from $225
- Apple (AAPL) down 1% after a new analyst taking over coverage of the stock at Jefferies downgraded shares to Hold from Buy
Symbols:
B NAPA PFE ALTM SRRK MULN TRVN AMZN AAPL Keywords: Fly Intel, Wall Street, Top Stories, Stocks